Výsledky vyhledávání - "L. Gaba Garcia"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

116P Real-world and in silico incidence of fibroblast growth factor receptor (FGFR) 1-4 molecular alterations across multiple cancer types

Publikováno v: Annals of Oncology. 32:S405-S406

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::623b7f3d7f198d7d9c2db9c9b2ae4931
https://doi.org/10.1016/j.annonc.2021.08.396

Zobrazit plný text záznamu

748P Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)

Publikováno v: Annals of Oncology. 32:S742-S743

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27f1fb00ad126dc19896f815a05741aa
https://doi.org/10.1016/j.annonc.2021.08.1190

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours

Publikováno v: Annals of Oncology. 31:S1418

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dcf1fad6350487eab115dc8634c9d6a5
https://doi.org/10.1016/j.annonc.2020.10.487

Zobrazit plný text záznamu

880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study

Autor: L. Gaba Garcia, Cristina Maria Churruca, Y. García, Ana Oaknin, M.P. Barretina Ginesta, Andrés Redondo, Beatriz Pardo, Ana Santaballa, Luis Manso, G. Villacampa Javierre, M. J. Rubio, Ignacio A. Romero, M. Iglesias, J.D. Alarcon, A. Sánchez, G Marquina, A. González Martín

Publikováno v: Annals of Oncology. 31:S645

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06dfe646305d9f56c3e4607ed98b088d
https://doi.org/10.1016/j.annonc.2020.08.1019

Zobrazit plný text záznamu

Implementation of a Pharmaceutical Care Programme for Patients Treated with Investigational Oral Drugs in a Clinical Trials Unit

Autor: N. Creus, Iván Victoria, F Do Pazo, G. Riu, L. Gaba Garcia, Laura Vidal, G. Molas, B. Gomez

Publikováno v: Annals of Oncology. 25:iv163

Background: Oral agents provide an attractive approach to chemotherapy and its use is increasing. However, it is necessary to educate the patient to achieve a correct adherence, avoid interactions and get a correct management of adverse effects. When

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e17211be21b4e52c58fdcf8b30598673
https://doi.org/10.1093/annonc/mdu331.48

Zobrazit plný text záznamu

Micrornas Expression in Blood Associated with Taxanes Response and Overall Survival in Metastatic Castration-Resistant Prostate Cancer

Autor: M. Marín-Aguilera, N. Jiménez, G. Carrera, Virginia pereira, Pere Gascón, L. Gaba Garcia, Òscar Reig, Begoña Mellado

Publikováno v: Annals of Oncology. 25:iv268

Aim: MicroRNAs (miRs) are non-coding RNAs that regulate gene expression of several genes involved in cancer. Because their stability, these small molecules are potential to be blood-based markers for cancer diagnosis, staging, prognosis and response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e3f5861023337b7a6762fb7984f3bbc
https://doi.org/10.1093/annonc/mdu336.27

Zobrazit plný text záznamu

Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)

Autor: Michael Merger, N. Morsli, M. Gil Martin, J. M. Del Campo, Laura Vidal, V. Rodriguez Freixinos, Martin Oliver Sailer, L. Gaba Garcia, B. Pardo Búrdalo, Ana Oaknin, A. Ballester

Publikováno v: Annals of Oncology. 25:iv310

Aim: Nintedanib (N) is an oral, triple angiokinase inhibitor of VEGF, PDGF and FGF signalling. A recent study showed that the addition of N to standard 1st-line chemotherapy significantly prolongs PFS (HR 0.84; p = 0.0239) in advanced EOC (epithelial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::afc8cff3591f589747ae1b342ac92d31
https://doi.org/10.1093/annonc/mdu338.15

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání